Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Pediatrics |
| Online Access: | http://dx.doi.org/10.1155/2014/571609 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566734566981632 |
|---|---|
| author | Nusrat Homaira William Rawlinson Thomas L. Snelling Adam Jaffe |
| author_facet | Nusrat Homaira William Rawlinson Thomas L. Snelling Adam Jaffe |
| author_sort | Nusrat Homaira |
| collection | DOAJ |
| description | Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendation is based on evidence of efficacy when used under clinical trial conditions. However the real-world effectiveness of palivizumab outside of clinical trials among different patient populations is not well established. We performed a systematic review focusing on postlicensure observational studies of the protective effect of palivizumab prophylaxis for reducing RSV-associated hospitalizations in infants and children at high risk of severe infection. We searched studies published in English between 1 January 1999 and August 2013 and identified 420 articles, of which 20 met the inclusion criteria. This review supports the recommended use of palivizumab for reducing RSV-associated hospitalization rates in premature infants born at gestational age < 33 weeks and in children with chronic lung and heart diseases. Data are limited to allow commenting on the protective effect of palivizumab among other high risk children, including those with Down syndrome, cystic fibrosis, and haematological malignancy, indicating further research is warranted in these groups. |
| format | Article |
| id | doaj-art-122c0385e80e40cf82cc6ea163223dc7 |
| institution | Kabale University |
| issn | 1687-9740 1687-9759 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Pediatrics |
| spelling | doaj-art-122c0385e80e40cf82cc6ea163223dc72025-02-03T01:03:14ZengWileyInternational Journal of Pediatrics1687-97401687-97592014-01-01201410.1155/2014/571609571609Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World PerspectiveNusrat Homaira0William Rawlinson1Thomas L. Snelling2Adam Jaffe3Disciplines of Paediatrics, School of Women’s and Children’s Health, UNSW, Sydney Children’s Hospital, Level 3, Emergency Wing, Randwick, Sydney, NSW 2031, AustraliaVirology Division, SEALS Microbiology, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, AustraliaTelethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, WA 6009, AustraliaDisciplines of Paediatrics, School of Women’s and Children’s Health, UNSW, Sydney Children’s Hospital, Level 3, Emergency Wing, Randwick, Sydney, NSW 2031, AustraliaInfection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendation is based on evidence of efficacy when used under clinical trial conditions. However the real-world effectiveness of palivizumab outside of clinical trials among different patient populations is not well established. We performed a systematic review focusing on postlicensure observational studies of the protective effect of palivizumab prophylaxis for reducing RSV-associated hospitalizations in infants and children at high risk of severe infection. We searched studies published in English between 1 January 1999 and August 2013 and identified 420 articles, of which 20 met the inclusion criteria. This review supports the recommended use of palivizumab for reducing RSV-associated hospitalization rates in premature infants born at gestational age < 33 weeks and in children with chronic lung and heart diseases. Data are limited to allow commenting on the protective effect of palivizumab among other high risk children, including those with Down syndrome, cystic fibrosis, and haematological malignancy, indicating further research is warranted in these groups.http://dx.doi.org/10.1155/2014/571609 |
| spellingShingle | Nusrat Homaira William Rawlinson Thomas L. Snelling Adam Jaffe Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective International Journal of Pediatrics |
| title | Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective |
| title_full | Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective |
| title_fullStr | Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective |
| title_full_unstemmed | Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective |
| title_short | Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective |
| title_sort | effectiveness of palivizumab in preventing rsv hospitalization in high risk children a real world perspective |
| url | http://dx.doi.org/10.1155/2014/571609 |
| work_keys_str_mv | AT nusrathomaira effectivenessofpalivizumabinpreventingrsvhospitalizationinhighriskchildrenarealworldperspective AT williamrawlinson effectivenessofpalivizumabinpreventingrsvhospitalizationinhighriskchildrenarealworldperspective AT thomaslsnelling effectivenessofpalivizumabinpreventingrsvhospitalizationinhighriskchildrenarealworldperspective AT adamjaffe effectivenessofpalivizumabinpreventingrsvhospitalizationinhighriskchildrenarealworldperspective |